Risk factors of radiation pneumonitis in patients with NSCLC treated with concomitant chemoradiotherapy--Are we underestimating diabetes?--Turkish oncology group (TOG)/Lung cancer study group [0.03%]
同时放化疗治疗的非小细胞肺癌放射性肺炎的风险因素：我们低估了糖尿病的影响吗？-土耳其肿瘤学会/肺癌研究小组
Sefika A Ergen,Fazilet O Dincbas,Birsen Yücel et al.
Sefika A Ergen et al.
Introduction: To evaluate the clinical and dosimetric parameters that increase the risk of radiation pneumonitis (RP) in locally advanced non-small cell lung cancer (NSCLC) patients treated with concomitant chemoradiother...
Adjuvant radiotherapy additionally to chemotherapy in resected node-positive small cell lung cancer: A role assessment without randomized evidence [0.03%]
辅助化疗以外的放疗在手术治疗后的淋巴结阳性小细胞肺癌中的作用评估（无随机对照研究证据）
Maurice Dantes,Lukas Käsmann,Olarn Roengvoraphoj et al.
Maurice Dantes et al.
Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy [0.03%]
重度至极重度慢性阻塞性肺疾病对非小细胞肺癌化疗患者预后的影响
Weigang Dong,Yaqian Zhu,Yan Du et al.
Weigang Dong et al.
Introduction: Chronic obstructive pulmonary disease (COPD) is associated with poor prognosis in non-small cell lung cancer (NSCLC) patients. There are limited data about the impact of severe-to-very severe COPD on prognos...
Observational Study
The clinical respiratory journal. 2020 Apr;14(4):345-352. DOI:10.1111/crj.13139 2020
Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy [0.03%]
预处理营养指数(PNI)对铂类化疗小细胞肺癌患者的临床影响
Shi Jin,Shoubo Cao,Shanqi Xu et al.
Shi Jin et al.
Introduction: Numbers of prognostic factors of small cell lung cancer (SCLC) have been demonstrated in previous studies. However, the identification of biomarkers with easy access, convenience, and low consumption is of g...
Neutrophil-lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy [0.03%]
中性粒细胞与淋巴细胞比率和一个剂量学因素用于预测同步放化疗非小细胞肺癌患者出现放射性肺炎症状的预后指标研究
Yun Hee Lee,Hoon-Sik Choi,Hojin Jeong et al.
Yun Hee Lee et al.
Objectives: To identify the factors that predict the progression of radiological radiation pneumonitis (RP) to symptomatic RP, and to evaluate the usefulness of the neutrophil-lymphocyte ratio (NLR) as a marker of RP seve...
Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy [0.03%]
肺癌化疗中单核细胞最低计数可能是中性粒细胞降低的指示指标
Yusuke Moriyama,Nobuyuki Horita,Makoto Kudo et al.
Yusuke Moriyama et al.
Introduction: No previous study clearly demonstrated the association between the absolute neutrophil count (ANC) nadir and the absolute monocyte count (AMC) nadir among patients undergoing chemotherapy. ...
Hyperpigmentation in palms associated with lung adenocarcinoma resolving after chemotherapy [0.03%]
与肺腺癌相关的手掌色素沉着在接受化疗后消失
Fengying Wu,Chunxia Su,Li Liu et al.
Fengying Wu et al.
Background and aim: Hyperpigmentation is a kind of paraneoplastic syndrome associated with lung cancer. Diffuse hyperpigmentation was reported and generally resulted from overproduction of melanocyte-stimulating hormone o...
Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy [0.03%]
根治性放疗联合卡铂-紫杉醇同步化疗治疗III期非小细胞肺癌的疗效分析
Hon Trinh,Mark Blayne Pinkham,Margot Lehman et al.
Hon Trinh et al.
Background and aim: Thoracic radiotherapy administered concurrently with chemotherapy is the standard of care for patients with inoperable stage III non-small cell lung cancer, but the optimal chemotherapy regimen is not ...
Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival [0.03%]
肺癌患者化疗反应及五年生存率不同的HLAI和II类等位基因分布特点分析
Omer Araz,Elif Yilmazel Ucar,Mehmet Meral et al.
Omer Araz et al.
Introduction: Lung cancer is the most common cause of cancer death in the world, and the most common type is non-small-cell lung cancer (NSCLC). At present, surgical resection, chemotherapy, and radiation therapy are the ...
Improving chemotherapy for patients with advanced non-small cell lung cancer [0.03%]
改善对晚期非小细胞肺癌患者的化学治疗
Christian von Plessen
Christian von Plessen
Introduction: Lung cancer is the third most common mortal disease in industrialised countries and the prognosis has been slow to improve. The largest subgroup has locally advanced or metastatic non-small cell lung cancer ...
Randomized Controlled Trial
The clinical respiratory journal. 2011 Jan;5(1):60-1. DOI:10.1111/j.1752-699X.2010.00199.x 2011